BrainCool AB (publ) obtains US patent approval

BrainCool AB, a Swedish based medical device cooling company, announces that the United States Patent and Trademark office has issued a Notice of Allowance for the US Patent Application No 14/266,600.

This patent approval results in further protection and extension of the protection for the catheter and cooling solution of BrainCool’s product RhinoChill.

BrainCool’s patent structure associated with this product consists of 4 patent families, where the product now has 12 granted US patents.

The patent families concern devices for cooling the nasal cavity, cooling of localized areas of the body for cerebral blood flow augmentation, methods and devices for non-invasive cerebral and systemic cooling via the nasal cavity, as well as methods and devices for non-invasive cerebral and systemic cooling for treating patients with either stroke or cardiogenic shock caused by reduced cerebral perfusion or in the treatment of migraines.

CEO Martin Waleij comments;

The extension of our patent protection concerning the RhinoChill product for early brain cooling and treatment of migraine, is a central component in the commercialization strategy of BrainCool.

For further information:

Martin Waleij - CEO

Phone: +46 - 733 -93 70 76

E-mail: martin.waleij@braincool.se

This information is information that BrainCool (publ) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, on September 4, 2017.

This press release has been published in English and Swedish. In the event of any discrepancy in content between the two versions, the English version will apply.